Navigation Links
EVT in Medical News

Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness

Statistical Significance in Primary and Key Secondary Endpoints at Both Doses Data Confirm Robust Sleep Onset and Sleep Maintenance Effects Seen in the First Phase II Study in the Adult Population HAMBURG, Germany and OXFORD, England, October 16 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt...

Alzheimer’s disease trial With EVT 101 For Successfully Complete

Alzheimer’s disease is a dreaded disease for the elderly. In the direction of its treatment , the effort of Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") has successfully completed the single ascending dose component // of the Phase I clinical study with EVT 101, a subtype-specific...
EVT in Medical Technology

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

Single-Dose, Volunteer fMRI Study Completed and Reported Today Dosing in Four Week Higher Repeat Dose Study Completed HAMBURG, Germany and OXFORD, England, March 28 /PRNewswire-FirstCall/ -- Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the preliminary findings of ...

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

Both Co-Primary Endpoints, Wake After Sleep Onset and Total Sleep Time, and Key Secondary Endpoints, Including Latency to Persistent Sleep, Were Met at Both Doses HAMBURG, Germany and OXFORD, England, June 04, 2007 /PRNewswire-FirstCall/ -- Evotec AG announced today positive top-line results from ...

Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...

... results from its first phase II clinical trial of evt 201 in patients with chronic primary insomnia. evt 201 is a partial positive allosteric modulator (pP...controlled cross-over study design of two doses of evt 201 (1.5mg and 2.5mg) in 67 patients was conducted...
EVT in Biological Technology

Evotec Starts Phase II in Smoking Cessation with EVT 302

HAMBURG, Germany and OXFORD, England, February 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B). This doubl...

Phase I Safety and Tolerability Study With EVT 302 Successfully Completed

HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 ...

Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201

Very Robust Findings on the Key Problems Faced by Insomniacs, i.e. Sleep Onset and Sleep Maintenance Evotec to Host a Conference Call Today at 11:00 am CET (10:00 am UK time, 5:00 am EST, 7:00 pm AEST) Directly From the Worldsleep07 Congress in Australia HAMBURG, Germany and OXFORD, England,...

Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia

HAMBURG, Germany and OXFORD, England, August 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at...

Evotec Announces Financial Results for 2007

... Positive data from two Phase II trials evaluating evt 201 strengthening confidence in evt 201's potential advantages over competitive insomnia therapies - Phase I safety data for evt 302 revealed good tolerance up to the highest d...

Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis

...logies acquired ("In-process Research and Development") in the amount of EUR 38.5 million, in particular to Evotec's clinical programs EVT 201 and the evt 100 series, which according to IFRS has to be capitalized and to be carried forward according to IAS 38. EUR 7.1 million was allocated to the customer...

Evotec Reports Third Quarter 2007 Results

... Phase II trials with lead insomnia drug candidate evt 201 - Sale of the Chemical Development Business t... two Phase II studies with insomnia drug candidate evt 201 - In adult insomniacs (first study), evt 201 showed highly statistically significant effect...

Evotec AG: R&D Update on 16 October 2007 Live on the Internet

...entral Nervous System. Evotec has three programmes in clinical development: evt 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor c...ceptor antagonist for the treatment of Alzheimer's disease and/or pain, and evt 302, a MAO-B inhibitor in development for smoking cessation. On 19 Septemb...

Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York

...entral Nervous System. Evotec has three programmes in clinical development: evt 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor c...ceptor antagonist for the treatment of Alzheimer's disease and/or pain, and evt 302, a MAO-B inhibitor in development for smoking cessation. http://www.e...
Other Tags
(Date:8/28/2014)... Albany, New York (PRWEB) August 28, 2014 ... is currently perceived with great interest among other healthcare ... due to the high demand in vaccine with respect ... also highly in demand due to an improved understanding ... individuals across the United States. It has led to ...
(Date:8/28/2014)... New York (PRWEB) August 28, 2014 ... that has spent many years fighting to ensure that ... the decision to provide coverage to WTC victims who ... by the U.S. Government Accountability Office (GAO). According to ... on August 25th, the report is entitled “World Trade ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Hastings and ... has been providing quality accident attorney services and other ... firm is proud to announce that it has saved ... that has been valued at over half of a ... Hastings provides genuine discount attorney's fees that result in ...
(Date:8/28/2014)... News) -- Having greater amounts of yellow pigment in ... objects in hazy conditions, a new study reports. ... hazy conditions in order to test the distance vision ... called macular pigment) in their eyes. The volunteers ... accumulations of the nutrients lutein and zeaxanthin, according to ...
(Date:8/28/2014)... Genetic testing for multiple diseases ... with large reference laboratories as well as smaller ... regard to the genetic variants analyzed, the methods ... to find the most appropriate laboratory providers for ... through these differences, Hayes, Inc. has added GTE ...
Breaking Medicine News(10 mins):Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $23,400 On Settlement Of $540,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $23,400 On Settlement Of $540,000 3Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Law Enforcement ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html About Biometrics ... individuals on the basis of their physical or ... of both physiological traits such as fingerprints, face ...
(Date:8/27/2014)... when it is related to ability that we already ... new melody more easily than learning how to hit ... for the Neural Basis of Cognition (CNBC)a joint program ... discovered a fundamental constraint in the brain that may ... in the Aug. 28, 2014, issue of Nature ...
(Date:8/27/2014)... Europe based upon a proxy for impact have been ... data, approach to scientific research. , The researchers from ... the top 100 pathogens affecting humans and the top ... believe, will help governments across the continent plan for ... as a result of climate change, and for biosecurity. ...
Breaking Biology News(10 mins):Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2
Other Contents